In cervical cancer [42], prostate cancer [43], and nasopharyngeal carcinoma [44], FOXM1 caused paclitaxel resistance by modulating the expression of ATP‐binding cassette subfamily C member 5 (ABCC5), in vitro and in vivo studies demonstrate that FOXM1‐specific inhibitors significantly weaken paclitaxel resistance. This evidence concerns the gene FOXM1 and prostate cancer.